MNG1042
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.330
- PROTEIN_SECRETION+0.311
- UV_RESPONSE_DN+0.311
- TGF_BETA_SIGNALING+0.295
- MITOTIC_SPINDLE+0.233
- MYC_TARGETS_V1+0.206
- ANDROGEN_RESPONSE+0.163
- UNFOLDED_PROTEIN_RESPONSE+0.135
- E2F_TARGETS+0.097
- PI3K_AKT_MTOR_SIGNALING+0.092
Top 10 suppressed
- ANGIOGENESIS-0.510
- TNFA_SIGNALING_VIA_NFKB-0.399
- APICAL_SURFACE-0.318
- ALLOGRAFT_REJECTION-0.297
- ESTROGEN_RESPONSE_LATE-0.291
- COMPLEMENT-0.289
- INFLAMMATORY_RESPONSE-0.274
- KRAS_SIGNALING_DN-0.253
- SPERMATOGENESIS-0.251
- KRAS_SIGNALING_UP-0.236
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1043 | — | — | 0.833 |
| 2 | MNG1224 | — | — | 0.813 |
| 3 | MDT-AP-0211 | Med | Medulloblastoma | 0.809 |
| 4 | MNG451 | — | — | 0.808 |
| 5 | MNG196 | — | — | 0.795 |
| 6 | MNG892 | — | — | 0.786 |
| 7 | MNG977 | — | — | 0.785 |
| 8 | MNG70 | — | — | 0.784 |
| 9 | MNG975 | — | — | 0.775 |
| 10 | 959c268c-637f-4f39-a254-a505c57e8448 | — | — | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.311 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.311 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.295 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.233 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.206 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.163 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.135 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.097 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.092 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.077 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.077 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.063 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.029 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.011 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.002 | Inavolisib | — uncovered |